

This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	Platelet derived growth factor receptor- β (PDGFRB); BRAF	<p><i>In vitro</i>, zebrafish and mouse studies identified a dual allosteric inhibitor of PDGFRB and BRAF that could help treat cancer. In mice, the inhibitor blocked angiogenesis and suppressed pancreatic and renal cancer growth compared with vehicle control. Next steps include studying the dual inhibitor in other preclinical cancer models. Kinagen Inc.'s KG5, a dual inhibitor that targets PDGFRB and BRAF, is in preclinical development to treat cancer.</p> <p>At least four companies have BRAF inhibitors in clinical and preclinical testing to treat cancer.</p> <p>SciBX 3(7); doi:10.1038/scibx.2010.212 Published online Feb. 18, 2010</p>	Findings patented; exclusively licensed to Kinagen	<p>Murphy, E. <i>et al. Proc. Natl. Acad. Sci. USA</i>; published Feb. 8, 2010; doi:10.1073/pnas.0909299107</p> <p>Contact: David A. Cheresch, University of California, San Diego, La Jolla, Calif. e-mail: dcheresh@ucsd.edu</p>